The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
CIRSE Standards of Practice on Hepatic Transarterial Chemoembolisation
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Arterial introducer sheaths ranging in size from 4 to 8 Fr are used in most interventional radiology procedures [1,2,3,4,5,6,7,8,9,10,11,12].”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Llovet, J. M., Kelley, R. K., Villanueva, A., Singal, A. G., Pikarsky, E., Roayaie, S., Lencioni, R., Koike, K., Zucman-Rossi, J., & Finn, R. S. (2021) · Nature Reviews Disease Primers · doi:10.1038/s41572-020-00240-3 · Cited by 7,055
Prognosis of Hepatocellular Carcinoma: The BCLC Staging Classification
Llovet, J., Brú, C., & Bruix, J. (1999) · Seminars in Liver Disease · doi:10.1055/s-2007-1007122 · Cited by 3,805
ESMO consensus guidelines for the management of patients with metastatic colorectal cancer
Van Cutsem, E., Cervantes, A., Adam, R., Sobrero, A., Van Krieken, J. H., Aderka, D., Aranda Aguilar, E., Bardelli, A., Benson, A., Bodoky, G., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw235 · Cited by 3,421
Research works printed but not linked: 157
- Basile A, Carrafiello G, Ierardi AM, Tsetis D. Brountzos E Quality-improvement guidelines for hepatic transarterial chemoembolization. Cardiovasc Intervent Radiol. 2012;35(4):765–74. · DOI
- Yamada R, Nakatsuka H, Nakamura K, et al. [Super-selective arterial embolization in unresectable hepatomas (author’s transl)] Nihon Igaku Hoshasen Gakkai zasshi. Nippon acta radiologica. 1979;39(5):540–3.
- Guan Y-S, He Q, Wang M-Q. Transcatheter arterial chemoembolization: history for more than 30 years. ISRN Gastroenterol. 2012;2012:1–8. · doi:10.5402/2012/480650
- Yamada R, Sato M, Kawabata M, Nakatsuka H, Nakamura K, Takashima S. Hepatic artery embolization in 120 patients with unresectable hepatoma. Radiology. 1983;148(2):397–401. · DOI · Paper page
- Craig P, Young S, Golzarian J. Current Trends in the Treatment of Hepatocellular Carcinoma with Transarterial Embolization: Variability in Technical Aspects. Cardiovasc Intervent Radiol. 2019;2(9):1322–8. · doi:10.1007/s00270-019-02232-7
- Young S, Craig P, Golzarian J. Current trends in the treatment of hepatocellular carcinoma with transarterial embolization: a cross-sectional survey of techniques. Eur Radiol. 2019;29(6):3287–95. · doi:10.1007/s00330-018-5782-7
- Sahara S, Kawai N, Sato M, et al. Prospective evaluation of transcatheter arterial chemoembolization (TACE) with multiple anti-cancer drugs (epirubicin, cisplatin, mitomycin c, 5-fluorouracil) compared with TACE with epirubicin for treatment of hepatocellular carcinoma. Cardiovasc Intervent Radiol. 2012;35(6):1363–71. · doi:10.1007/s00270-012-0352-x
- Hong K, Khwaja A, Liapi E, Torbenson MS, Georgiades CS, Geschwind JF. New intra-arterial drug delivery system for the treatment of liver cancer: preclinical assessment in a rabbit model of liver cancer. Clini cancer res Official J Am Assoc Cancer Res. 2006;12(8):2563–7. · doi:10.1158/1078-0432.ccr-05-2225
- Lammer J, Malagari K, Vogl T, et al. Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. Cardiovasc Intervent Radiol. 2010;33(1):41–52. · DOI · Paper page
- Iezzi R, Pompili M, Rinninella E, et al. TACE with degradable starch microspheres (DSM-TACE) as second-line treatment in HCC patients dismissing or ineligible for sorafenib. Eur Radiol. 2019;29(3):1285–92. · DOI
- Gross A, Albrecht T. Transarterial Chemoembolisation (TACE) with Degradable Starch Microspheres (DSM) and Anthracycline in Patients with Locally Extensive Hepatocellular Carcinoma (HCC): Safety and Efficacy. Cardiovasc Intervent Radiol. 2020;43(3):402–10. · doi:10.1007/s00270-019-02364-w
- Schicho A, Pereira PL, Haimerl M, et al. Transarterial chemoembolization (TACE) with degradable starch microspheres (DSM) in hepatocellular carcinoma (HCC): multi-center results on safety and efficacy. Oncotarget. 2017;8(42):72613–20. · doi:10.18632/oncotarget.19997
- Goerg F, Zimmermann M, Bruners P, Neumann U, Luedde T, Kuhl C. Chemoembolization with Degradable Starch Microspheres for Treatment of Patients with Primary or Recurrent Unresectable, Locally Advanced Intrahepatic Cholangiocarcinoma: A Pilot Study. Cardiovasc Intervent Radiol. 2019;42(12):1709–17. · doi:10.1007/s00270-019-02344-0
- Schicho A, Pereira PL, Michalik K, Beyer LP, Stroszczynski C, Wiggermann P. Safety and efficacy of transarterial chemoembolization with degradable starch microspheres (DSM-TACE) in the treatment of secondary liver malignancies. Onco Targets Ther. 2018;11:345–50. · doi:10.2147/ott.s147852
- Irie T, Kuramochi M, Takahashi N. Dense accumulation of lipiodol emulsion in hepatocellular carcinoma nodule during selective balloon-occluded transarterial chemoembolization: measurement of balloon-occluded arterial stump pressure. Cardiovasc Intervent Radiol. 2013;36(3):706–13. · DOI
- Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. · DOI · Paper page
- Gaba RC, Lokken RP, Hickey RM, et al. Quality Improvement Guidelines for Transarterial Chemoembolization and Embolization of Hepatic Malignancy. J Vasc Interv Radiol. 2017;28(9):1210–23. · DOI
- Riihimaki M, Hemminki A, Sundquist K, Sundquist J, Hemminki K. The epidemiology of metastases in neuroendocrine tumors. Int J Cancer. 2016;139(12):2679–86. · DOI · Paper page
- Mitchell DG, Bruix J, Sherman M, Sirlin CB. LI-RADS (Liver Imaging Reporting and Data System): Summary, discussion, and consensus of the LI-RADS Management Working Group and future directions. Hepatology. 2015;61(3):1056–65. · DOI · Paper page
- Di Tommaso L, Spadaccini M, Donadon M, et al. Role of liver biopsy in hepatocellular carcinoma. World J Gastroenterol. 2019;25(40):6041–52. · DOI
- Lencioni R, Petruzzi P, Crocetti L. Chemoembolization of hepatocellular carcinoma. Semin Intervent Radiol. 2013;30(1):3–11. · DOI · Paper page
- Shin SW. The current practice of transarterial chemoembolization for the treatment of hepatocellular carcinoma. Korean J Radiol. 2009;10(5):425–34. · doi:10.3348/kjr.2009.10.5.425
- Schraml C, Kaufmann S, Rempp H, et al. Imaging of HCC-Current State of the Art. Diagnostics. 2015;5(4):513–45. · DOI
- Golfieri R, Renzulli M, Mosconi C, et al. Hepatocellular carcinoma responding to superselective transarterial chemoembolization: an issue of nodule dimension? J Vasc Interv Radiol. 2013;24(4):509–17. · DOI
- Miura JT, Rilling WS, White SB, et al. Safety and efficacy of transarterial chemoembolization in patients with transjugular intrahepatic portosystemic shunts. HPB. 2015;17(8):707–12. · doi:10.1111/hpb.12433
- Vogel A, Cervantes A, Chau I, et al. Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018;29:238–55. · DOI · Paper page
- de Baere T, Deschamps F, Tselikas L, et al. GEP-NETS update: Interventional radiology: role in the treatment of liver metastases from GEP-NETs. Eur J Endocrinol. 2015;172(4):R151-166. · doi:10.1530/eje-14-0630
- Tangkijvanich P, Anukulkarnkusol N, Suwangool P, et al. Clinical characteristics and prognosis of hepatocellular carcinoma: analysis based on serum alpha-fetoprotein levels. J Clin Gastroenterol. 2000;31(4):302–8. · DOI · Paper page
- Arai T, Kobayashi A, Ohya A, et al. Assessment of treatment outcomes based on tumor marker trends in patients with recurrent hepatocellular carcinoma undergoing trans-catheter arterial chemo-embolization. Int J Clin Oncol. 2014;19(5):871–9. · doi:10.1007/s10147-013-0634-6
- Yu R, Tan Z, Xiang X, Dan Y, Deng G. Effectiveness of PIVKA-II in the detection of hepatocellular carcinoma based on real-world clinical data. BMC Cancer. 2017;17(1):608. · DOI
- Michl M, Koch J, Laubender RP, et al. Tumor markers CEA and CA 19–9 correlate with radiological imaging in metastatic colorectal cancer patients receiving first-line chemotherapy. Tumour Biol. 2014;35(10):10121–7. · doi:10.1007/s13277-014-2280-7
- Pavel M, Öberg K, Falconi M, et al. Gastroenteropancreatic neuroendocrine neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020;31(7):844–60. · DOI · Paper page
- EASL Clinical Practice Guidelines. Management of hepatocellular carcinoma. J Hepatol. 2018;69(1):182–236. · DOI · Paper page
- Johnson PJ, Berhane S, Kagebayashi C, et al. Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-the ALBI grade. J Clin Oncol. 2015;33(6):550–8. · DOI · Paper page
- Abdel-Rahman O. Prognostic Value of Baseline ALBI Score Among Patients With Colorectal Liver Metastases: A Pooled Analysis of Two Randomized Trials. Clin Colorectal Cancer. 2019;18(1):e61–8. · DOI
- Rebonato A, Graziosi L, Maiettini D, et al. Inflammatory Markers as Prognostic Factors of Survival in Patients Affected by Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization. Gastroenterol Res Pract. 2017;2017:4164130–4164130. · doi:10.1155/2017/4164130
- Lee MJ, Fanelli F, Haage P, Hausegger K, Van Lienden KP. Patient safety in interventional radiology: a CIRSE IR checklist. Cardiovasc Intervent Radiol. 2012;35(2):244–6. · DOI
- Ogasawara S, Chiba T, Ooka Y, et al. A randomized placebo-controlled trial of prophylactic dexamethasone for transcatheter arterial chemoembolization. Hepatology. 2018;67(2):575–85. · DOI
- Iezzi R, Kovacs A, Prenen H, Chevallier P, Pereira PL. Transarterial chemoembolisation of colorectal liver metastases with irinotecan-loaded beads: What every interventional radiologist should know. Eur J Radiol Open. 2020;7:100236. · DOI
- Wang TC, Zhang ZS, Xiao YD. Determination of Risk Factors for Pain After Transarterial Chemoembolization with Drug-Eluting Beads for Hepatocellular Carcinoma. J Pain Res. 2020;13:649–56. · doi:10.2147/jpr.s246197
- Benzakoun J, Ronot M, Lagadec M, et al. Risks factors for severe pain after selective liver transarterial chemoembolization. Liver Int. 2017;37(4):583–91. · doi:10.1111/liv.13235
- Romagnoli S, Fanelli F, et al. CIRSE Standards of Practice on Analgesia and Sedation for Interventional Radiology in Adults. Cardiovasc Intervent Radiol. 2020;43(9):1251–60. · doi:10.1007/s00270-020-02536-z
- Chehab MA, Thakor AS, Tulin-Silver S, et al. Adult and Pediatric Antibiotic Prophylaxis during Vascular and IR Procedures: A Society of Interventional Radiology Practice Parameter Update Endorsed by the Cardiovascular and Interventional Radiological Society of Europe and the Canadian Association for Interventional Radiology. J Vasc Interv Radiol. 2018;29(11):1483-1501.e1482. · DOI · Paper page
- Patel IJ, Davidson JC, Nikolic B, et al. Consensus guidelines for periprocedural management of coagulation status and hemostasis risk in percutaneous image-guided interventions. J Vasc Interv Radiol. 2012;23(6):727–36. · DOI · Paper page
- Hadi M, Walker C, Desborough M, et al. CIRSE Standards of Practice on Peri-operative Anticoagulation Management During Interventional Radiology Procedures. Cardiovasc Intervent Radiol. 2021;44(4):523–36. · DOI
- Lucatelli P, Corona M, Argiro R, et al. Impact of 3D Rotational Angiography on Liver Embolization Procedures: Review of Technique and Applications. Cardiovasc Intervent Radiol. 2015;38(3):523–35. · doi:10.1007/s00270-014-1023-x
- Pung L, Ahmad M, Mueller K, et al. The Role of Cone-Beam CT in Transcatheter Arterial Chemoembolization for Hepatocellular Carcinoma: A Systematic Review and Meta-analysis. J Vasc Interv Radiol. 2017;28(3):334–41. · DOI
- Lucatelli P, De Rubeis G, Ginnani Corradini L, et al. Intra-procedural dual phase cone beam computed tomography has a better diagnostic accuracy over pre-procedural MRI and MDCT in detection and characterization of HCC in cirrhotic patients undergoing TACE procedure. Eur J Radiol. 2020;124:108806. · doi:10.1016/j.ejrad.2019.108806
- Lucatelli P, Argiro R, Bascetta S, et al. Single injection dual phase CBCT technique ameliorates results of trans-arterial chemoembolization for hepatocellular cancer. Transl Gastroenterol Hepatol. 2017;2:83. · doi:10.21037/tgh.2017.10.03
- Schernthaner RE, Haroun RR, Duran R, et al. Improved Visibility of Metastatic Disease in the Liver During Intra-Arterial Therapy Using Delayed Arterial Phase Cone-Beam CT. Cardiovasc Intervent Radiol. 2016;39(10):1429–37. · doi:10.1007/s00270-016-1406-2
- Kan Z, Ivancev K, Hägerstrand I, Chuang VP, Lunderquist A. In vivo microscopy of the liver after injection of Lipiodol into the hepatic artery and portal vein in the rat. Acta Radiol. 1989;30(4):419–25. · DOI
- Tanaka T, Arai Y, Inaba Y, et al. Current role of hybrid CT/angiography system compared with C-arm cone beam CT for interventional oncology. Br J Radiol. 2014;87(1041):20140126. · doi:10.1259/bjr.20140126
- Toyoda H, Kumada T, Sone Y. Impact of a Unified CT Angiography System on Outcome of Patients with Hepatocellular Carcinoma. Am J Roentgenol. 2009;192(3):766–74. · doi:10.2214/ajr.08.1368
- de Baere T, Dufaux J, Roche A, et al. Circulatory alterations induced by intra-arterial injection of iodized oil and emulsions of iodized oil and doxorubicin: experimental study. Radiology. 1995;194(1):165–70. · doi:10.1148/radiology.194.1.7997545
- Takayasu K, Shima Y, Muramatsu Y, et al. Hepatocellular carcinoma: treatment with intraarterial iodized oil with and without chemotherapeutic agents. Radiology. 1987;163(2):345–51. · doi:10.1148/radiology.163.2.3031724
- Idée JM, Guiu B. Use of Lipiodol as a drug-delivery system for transcatheter arterial chemoembolization of hepatocellular carcinoma: a review. Crit Rev Oncol Hematol. 2013;88(3):530–49. · DOI · Paper page
- Deschamps F, Farouil G, Gonzalez W, et al. Stabilization Improves Theranostic Properties of Lipiodol(®)-Based Emulsion During Liver Trans-arterial Chemo-embolization in a VX2 Rabbit Model. Cardiovasc Intervent Radiol. 2017;40(6):907–13. · doi:10.1007/s00270-017-1616-2
- de Baere T, Zhang X, Aubert B, et al. Quantification of tumor uptake of iodized oils and emulsions of iodized oils: experimental study. Radiology. 1996;201(3):731–5. · doi:10.1148/radiology.201.3.8939223
- Kan Z, Wright K, Wallace S. Ethiodized oil emulsions in hepatic microcirculation: in vivo microscopy in animal models. Acad Radiol. 1997;4(4):275–82. · doi:10.1016/s1076-6332(97)80029-3
- de Baere T, Arai Y, Lencioni R, et al. Treatment of Liver Tumors with Lipiodol TACE: Technical Recommendations from Experts Opinion. Cardiovasc Intervent Radiol. 2016;39(3):334–43. · DOI · Paper page
- Kudo T, Monzawa S, Sugimura K. Evaluation of durability of three-way stopcocks to Lipiodol in making an emulsion for transcatheter arterial chemo-embolization. Medical Journal of Kobe University. 2004;64:47–52.
- Boulin M, Schmitt A, Delhom E, et al. Improved stability of lipiodol-drug emulsion for transarterial chemoembolisation of hepatocellular carcinoma results in improved pharmacokinetic profile: Proof of concept using idarubicin. Eur Radiol. 2016;26(2):601–9. · DOI
- Deschamps F, Moine L, Isoardo T, et al. Parameters for Stable Water-in-Oil Lipiodol Emulsion for Liver Trans-Arterial Chemo-Embolization. Cardiovasc Intervent Radiol. 2017;40(12):1927–32. · doi:10.1007/s00270-017-1763-5
- Nakamura H, Hashimoto T, Oi H, Sawada S. Transcatheter oily chemoembolization of hepatocellular carcinoma. Radiology. 1989;170(3 Pt 1):783–6. · doi:10.1148/radiology.170.3.2536946
- Tzeng WS, Wu RH, Chang SC, et al. Ionic versus nonionic contrast media solvents used with an epirubicin-based agent for transarterial chemoembolization of hepatocellular carcinoma. J Vasc Interv Radiol. 2008;19(3):342–50. · doi:10.1016/j.jvir.2007.10.021
- Gaba RC, Baumgarten S, Omene BO, et al. Ethiodized oil uptake does not predict doxorubicin drug delivery after chemoembolization in VX2 liver tumors. J Vasc Interv Radiol. 2012;23(2):265–73. · doi:10.1016/j.jvir.2011.10.022
- Chung JW, Park JH, Im JG, Han JK, Han MC. Pulmonary oil embolism after transcatheter oily chemoembolization of hepatocellular carcinoma. Radiology. 1993;187(3):689–93. · doi:10.1148/radiology.187.3.8388567
- Louail B, Sapoval M, Bonneau M, Wasseff M, Senechal Q, Gaux JC. A new porcine sponge material for temporary embolization: an experimental short-term pilot study in swine. Cardiovasc Intervent Radiol. 2006;29(5):826–31. · doi:10.1007/s00270-004-0299-7
- Katsumori T, Kasahara T. The size of gelatin sponge particles: differences with preparation method. Cardiovasc Intervent Radiol. 2006;29(6):1077–83. · doi:10.1007/s00270-006-0059-y
- Laurent A, Wassef M, Chapot R, et al. Partition of calibrated tris-acryl gelatin microspheres in the arterial vasculature of embolized nasopharyngeal angiofibromas and paragangliomas. J Vasc Interv Radiol. 2005;16(4):507–13. · doi:10.1097/01.rvi.0000150038.99488.01
- Lee KH, Liapi E, Vossen JA, et al. Distribution of iron oxide-containing Embosphere particles after transcatheter arterial embolization in an animal model of liver cancer: evaluation with MR imaging and implication for therapy. J Vasc Interv Radiol. 2008;19(10):1490–6. · doi:10.1016/j.jvir.2008.06.008
- Bonomo G, Pedicini V, Monfardini L, et al. Bland embolization in patients with unresectable hepatocellular carcinoma using precise, tightly size-calibrated, anti-inflammatory microparticles: first clinical experience and one-year follow-up. Cardiovasc Intervent Radiol. 2010;33(3):552–9. · DOI
- Miyayama S, Matsui O, Yamashiro M, et al. Ultraselective transcatheter arterial chemoembolization with a 2-f tip microcatheter for small hepatocellular carcinomas: relationship between local tumor recurrence and visualization of the portal vein with iodized oil. J Vasc Interv Radiol. 2007;18(3):365–76. · DOI · Paper page
- de Baere T, Plotkin S, Yu R, Sutter A, Wu Y, Cruise GM. An In Vitro Evaluation of Four Types of Drug-Eluting Microspheres Loaded with Doxorubicin. J Vasc Interv Radiol. 2016;27(9):1425–31. · doi:10.1016/j.jvir.2016.05.015
- Varela M, Real MI, Burrel M, et al. Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics. J Hepatol. 2007;46(3):474–81. · DOI · Paper page
- Volkova M, Russell R 3rd. Anthracycline cardiotoxicity: prevalence, pathogenesis and treatment. Curr Cardiol Rev. 2011;7(4):214–20. · DOI · Paper page
- McGowan JV, Chung R, Maulik A, Piotrowska I, Walker JM, Yellon DM. Anthracycline Chemotherapy and Cardiotoxicity. Cardiovasc Drugs Ther. 2017;31(1):63–75. · DOI · Paper page
- Veloso Gomes F, Oliveira JA, Correia MT, et al. Chemoembolization of Hepatocellular Carcinoma with Drug-Eluting Polyethylene Glycol Embolic Agents: Single-Center Retrospective Analysis in 302 Patients. J Vasc Interv Radiol. 2018;29(6):841–9. · doi:10.1016/j.jvir.2018.02.004
- Aliberti C, Carandina R, Lonardi S, et al. Transarterial Chemoembolization with Small Drug-Eluting Beads in Patients with Hepatocellular Carcinoma: Experience from a Cohort of 421 Patients at an Italian Center. J Vasc Interv Radiol. 2017;28(11):1495–502. · doi:10.1016/j.jvir.2017.07.020
- Aal AKA, Moawad S, Lune PV, et al. Survival Outcomes of Very Small Drug-Eluting Beads Used in Chemoembolization of Unresectable Hepatocellular Carcinoma. J Vasc Interv Radiol. 2019;30(9):1325-1334.e1322. · doi:10.1016/j.jvir.2019.05.006
- Richter G, Radeleff B, Stroszczynski C, et al. Safety and Feasibility of Chemoembolization with Doxorubicin-Loaded Small Calibrated Microspheres in Patients with Hepatocellular Carcinoma: Results of the MIRACLE I Prospective Multicenter Study. Cardiovasc Intervent Radiol. 2018;41(4):587–93. · doi:10.1007/s00270-017-1839-2
- Balli H, Aksungur E, Khalatai B, Aikimbaev K. Super-Selective Transarterial Chemoembolization with Doxorubicin-Loaded Drug-Eluting Beads Sized Below and Above 100 Microns in Hepatocellular Carcinoma: A Comparative Study. J Belg Soc Radiol. 2019;103(1):47. · doi:10.5334/jbsr.1841
- Delicque J, Guiu B, Boulin M, Schwanz H, Piron L, Cassinotto C. Liver chemoembolization of hepatocellular carcinoma using TANDEM((R)) microspheres. Future Oncol. 2018;14(26):2761–72. · doi:10.2217/fon-2018-0237
- Greco G, Cascella T, Facciorusso A, et al. Transarterial chemoembolization using 40 µm drug eluting beads for hepatocellular carcinoma. World J Radiol. 2017;9(5):245–52. · doi:10.4329/wjr.v9.i5.245
- Malagari K, Pomoni M, Moschouris H, et al. Chemoembolization of hepatocellular carcinoma with HepaSphere 30–60 μm Safety and efficacy study. Cardiovasc Intervent Radiol. 2014;37(1):165–75. · doi:10.1007/s00270-013-0777-x
- Deipolyi AR, Oklu R, Al-Ansari S, Zhu AX, Goyal L, Ganguli S. Safety and efficacy of 70–150 mum and 100–300 mum drug-eluting bead transarterial chemoembolization for hepatocellular carcinoma. J Vasc Interv Radiol. 2015;26(4):516–22. · doi:10.1016/j.jvir.2014.12.020
- Lucatelli P, Argirò R, De Rubeis G, et al. Polyethylene Glycol Epirubicin-Loaded Transcatheter Arterial Chemoembolization Procedures Utilizing a Combined Approach with 100 and 200 μm Microspheres: A Promising Alternative to Current Standards. J Vasc Interv Radiol. 2019;30(3):305–13. · doi:10.1016/j.jvir.2018.10.026
- Lencioni R, de Baere T, Burrel M, et al. Transcatheter treatment of hepatocellular carcinoma with Doxorubicin-loaded DC Bead (DEBDOX): technical recommendations. Cardiovasc Intervent Radiol. 2012;35(5):980–5. · DOI · Paper page
- Schernthaner RE, Lin M, Duran R, Chapiro J, Wang Z, Geschwind JF. Delayed-Phase Cone-Beam CT Improves Detectability of Intrahepatic Cholangiocarcinoma During Conventional Transarterial Chemoembolization. Cardiovasc Intervent Radiol. 2015;38(4):929–36. · doi:10.1007/s00270-014-1026-7
- Akinwande OK, Philips P, Duras P, Pluntke S, Scoggins C, Martin RC. Small versus large-sized drug-eluting beads (DEBIRI) for the treatment of hepatic colorectal metastases: a propensity score matching analysis. Cardiovasc Intervent Radiol. 2015;38(2):361–71. · DOI
- Yamasaki T, Hamabe S, Saeki I, et al. A novel transcatheter arterial infusion chemotherapy using iodized oil and degradable starch microspheres for hepatocellular carcinoma: a prospective randomized trial. J Gastroenterol. 2011;46(3):359–66. · doi:10.1007/s00535-010-0306-5
- Lucatelli P, De Rubeis G, Basilico F, et al. Sequential dual-phase cone-beam CT is able to intra-procedurally predict the one-month treatment outcome of multi-focal HCC, in course of degradable starch microsphere TACE. Radiol Med (Torino). 2019;124(12):1212–9. · doi:10.1007/s11547-019-01076-y
- Aramburu J, Anton R, Rivas A, et al. Numerical zero-dimensional hepatic artery hemodynamics model for balloon-occluded transarterial chemoembolization. Int J Numer Method Biomed Eng. 2018;34(7):e2983. · doi:10.1002/cnm.2983
- Lucatelli P, Corradini LG, De Rubeis G, et al. Balloon-Occluded Transcatheter Arterial Chemoembolization (b-TACE) for Hepatocellular Carcinoma Performed with Polyethylene-Glycol Epirubicin-Loaded Drug-Eluting Embolics: Safety and Preliminary Results. Cardiovasc Intervent Radiol. 2019;42(6):853–62. · doi:10.1007/s00270-019-02192-y
- Matsumoto T, Endo J, Hashida K, et al. Balloon-occluded transarterial chemoembolization using a 1.8-French tip coaxial microballoon catheter for hepatocellular carcinoma: technical and safety considerations. Minim Invasive Ther Allied Technol. 2015;24(2):94–100. · doi:10.3109/13645706.2014.951657
- Reicher J, Mafeld S, Priona G, et al. Early Experience of Trans-arterial Chemo-Embolisation for Hepatocellular Carcinoma with a Novel Radiopaque Bead. Cardiovasc Intervent Radiol. 2019;42(11):1563–70. · doi:10.1007/s00270-019-02317-3
- Aliberti C, Carandina R, Sarti D, et al. Transarterial chemoembolization with DC Bead LUMITM radiopaque beads for primary liver cancer treatment: preliminary experience. Future Oncol. 2017;13(25):2243–52. · doi:10.2217/fon-2017-0364
- Moschouris H, Malagari K, Dimakis A, Kiakidis T, Anagnostopoulou A. Transarterial Chemoembolization of HCC with Radiopaque Microspheres: Evaluation with Computed Tomography and the Complementary Role of Contrast-Enhanced Ultrasonography. Cardiovasc Intervent Radiol. 2020;43(7):1075–83. · doi:10.1007/s00270-020-02487-5
- Hagan A, Caine M, Press C, et al. Predicting pharmacokinetic behaviour of drug release from drug-eluting embolization beads using in vitro elution methods. Eur J Pharm Sci. 2019;136:104943. · doi:10.1016/j.ejps.2019.05.021
- Tacher V, Radaelli A, Lin M, Geschwind J-F. How I Do It: Cone-Beam CT during Transarterial Chemoembolization for Liver Cancer. Radiology. 2015;274(2):320–34. · doi:10.1148/radiol.14131925
- Forner A, Reig ME, Rodriguez de Lope C, Bruix J. Current Strategy for Staging and Treatment The BCLC Update and Future Prospects. Seminars in liver disease. 2010;30(1):061–074. · DOI · Paper page
- Lo CM, Ngan H, Tso WK, et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology. 2002;35(5):1164–71. · DOI · Paper page
- Llovet JM, Real MI, Montaña X, et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet. 2002;359(9319):1734–9. · DOI · Paper page
- Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival. Hepatology. 2003;37(2):429–42. · DOI · Paper page
- Cammà C, Schepis F, Orlando A, et al. Transarterial chemoembolization for unresectable hepatocellular carcinoma: meta-analysis of randomized controlled trials. Radiology. 2002;224(1):47–54. · DOI · Paper page
- Golfieri R, Giampalma E, Renzulli M, et al. Randomised controlled trial of doxorubicin-eluting beads vs conventional chemoembolisation for hepatocellular carcinoma. Br J Cancer. 2014;111(2):255–64. · DOI · Paper page
- Facciorusso A, Di Maso M, Muscatiello N. Drug-eluting beads versus conventional chemoembolization for the treatment of unresectable hepatocellular carcinoma: A meta-analysis. Digestive Liver Dis. 2016;48(6):571–7. · DOI · Paper page
- Yang B, Liang J, Qu Z, Yang F, Liao Z, Gou H. Transarterial strategies for the treatment of unresectable hepatocellular carcinoma: A systematic review. PLoS ONE. 2020;15(2):e0227475. · doi:10.1371/journal.pone.0227475
- Auer TA, Jonczyk M, Collettini F, et al. Trans-arterial chemoembolization with degradable starch microspheres (DSM-TACE) versus selective internal radiation therapy (SIRT) in multifocal hepatocellular carcinoma. Acta Radiol. 2020;62(3):313–21. · doi:10.1177/0284185120926474
- Ogawa M, Takayasu K, Hirayama M, et al. Efficacy of a microballoon catheter in transarterial chemoembolization of hepatocellular carcinoma using miriplatin, a lipophilic anticancer drug: Short-term results. Hepatol Res official J Japan Soc Hepatol. 2016;46(3):E60-69. · doi:10.1111/hepr.12527
- Irie T, Kuramochi M, Kamoshida T, Takahashi N. Selective balloon-occluded transarterial chemoembolization for patients with one or two hepatocellular carcinoma nodules: Retrospective comparison with conventional super-selective TACE. Hepatol Res official J Japan Soc Hepatol. 2016;46(2):209–14. · doi:10.1111/hepr.12564
- Maruyama M, Yoshizako T, Nakamura T, Nakamura M, Yoshida R, Kitagaki H. Initial Experience with Balloon-Occluded Trans-catheter Arterial Chemoembolization (B-TACE) for Hepatocellular Carcinoma. Cardiovasc Intervent Radiol. 2016;39(3):359–66. · doi:10.1007/s00270-015-1237-6
- Goldman DT, Singh M, Patel RS, et al. Balloon-Occluded Transarterial Chemoembolization for the Treatment of Hepatocellular Carcinoma: A Single-Center US Preliminary Experience. J Vasc Interv Radiol. 2019;30(3):342–6. · doi:10.1016/j.jvir.2018.11.026
- Golfieri R, Bezzi M, Verset G, et al. Retrospective European Multicentric Evaluation of Selective Transarterial Chemoembolisation with and without Balloon-Occlusion in Patients with Hepatocellular Carcinoma: A Propensity Score Matched Analysis. Cardiovasc Intervent Radiol. 2021;44(7):1048–59. · doi:10.1007/s00270-021-02805-5
- Vogl TJ, Wissniowski TT, Naguib NN, et al. Activation of tumor-specific T lymphocytes after laser-induced thermotherapy in patients with colorectal liver metastases. Cancer Immunol Immunother. 2009;58(10):1557–63. · doi:10.1007/s00262-009-0663-1
- Albert M, Kiefer MV, Sun W, et al. Chemoembolization of colorectal liver metastases with cisplatin, doxorubicin, mitomycin C, ethiodol, and polyvinyl alcohol. Cancer. 2011;117(2):343–52. · DOI
- Martin RC, Joshi J, Robbins K, et al. Hepatic intra-arterial injection of drug-eluting bead, irinotecan (DEBIRI) in unresectable colorectal liver metastases refractory to systemic chemotherapy: results of multi-institutional study. Ann Surg Oncol. 2011;18(1):192–8. · DOI · Paper page
- Fiorentini G, Aliberti C, Tilli M, et al. Intra-arterial infusion of irinotecan-loaded drug-eluting beads (DEBIRI) versus intravenous therapy (FOLFIRI) for hepatic metastases from colorectal cancer: final results of a phase III study. Anticancer Res. 2012;32(4):1387–95.
- Iezzi R, Marsico VA, Guerra A, et al. Trans-Arterial Chemoembolization with Irinotecan-Loaded Drug-Eluting Beads (DEBIRI) and Capecitabine in Refractory Liver Prevalent Colorectal Metastases: A Phase II Single-Center Study. Cardiovasc Intervent Radiol. 2015;38(6):1523–31. · DOI
- Levy J, Zuckerman J, Garfinkle R, et al. Intra-arterial therapies for unresectable and chemorefractory colorectal cancer liver metastases: a systematic review and meta-analysis. HPB. 2018;20(10):905–15. · doi:10.1016/j.hpb.2018.04.001
- Pereira PL, et al. The CIREL Cohort: A Prospective Controlled Registry Studying the Real-Life Use of Irinotecan-Loaded Chemoembolisation in Colorectal Cancer Liver Metastases: Interim Analysis. CardioVasc Interv Radiol. 2020;44:50–62. · DOI
- Bridgewater J, Galle PR, Khan SA, Llovet JM, Park JW, Patel T, Pawlik TM, Gores GJ. Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma. J Hepatol. 2014;60(6):1268–89. · DOI · Paper page
- Hyder O, Marsh JW, Salem R, et al. Intra-arterial therapy for advanced intrahepatic cholangiocarcinoma: a multi-institutional analysis. Ann Surg Oncol. 2013;20(12):3779–86. · DOI
- Filippi L, Schillaci O, Cianni R, Bagni O. Yttrium-90 resin microspheres and their use in the treatment of intrahepatic cholangiocarcinoma. Future Oncol. 2018;14(9):809–18. · doi:10.2217/fon-2017-0443
- Labib PL, Davidson BR, Sharma RA, Pereira SP. Locoregional therapies in cholangiocarcinoma. Hepat Oncol. 2017;4(4):99–109. · doi:10.2217/hep-2017-0014
- Schicho A, Pereira PL, Pützler M, et al. Degradable Starch Microspheres Transcatheter Arterial Chemoembolization (DSM-TACE) in Intrahepatic Cholangiocellular Carcinoma (ICC): Results from a National Multi-Center Study on Safety and Efficacy. Med Sci Monit. 2017;23:796–800. · doi:10.12659/msm.902901
- Do Minh D, Chapiro J, Gorodetski B, et al. Intra-arterial therapy of neuroendocrine tumour liver metastases: comparing conventional TACE, drug-eluting beads TACE and yttrium-90 radioembolisation as treatment options using a propensity score analysis model. Eur Radiol. 2017;27(12):4995–5005. · DOI
- Da Dong X, Carr BI. Hepatic artery chemoembolization for the treatment of liver metastases from neuroendocrine tumors: a long-term follow-up in 123 patients. Med Oncol. 2011;28(1):286–90. · doi:10.1007/s12032-010-9750-6
- Gaba RC, Lewandowski RJ, Hickey R, et al. Transcatheter Therapy for Hepatic Malignancy: Standardization of Terminology and Reporting Criteria. J Vasc Interv Radiol. 2016;27(4):457–73. · DOI
- Filippiadis DK, Binkert C, Pellerin O, Hoffmann RT, Krajina A, Pereira PL. Cirse Quality Assurance Document and Standards for Classification of Complications: The Cirse Classification System. Cardiovasc Intervent Radiol. 2017;40(8):1141–6. · DOI · Paper page
- Vera R, Aparicio J, Carballo F, et al. Recommendations for follow-up of colorectal cancer survivors. Clin Transl Oncol. 2019;21(10):1302–11. · DOI
- Singh S, Moody L, Chan DL, et al. Follow-up Recommendations for Completely Resected Gastroenteropancreatic Neuroendocrine Tumors. JAMA Oncol. 2018;4(11):1597–604. · DOI
- Rahnemai-Azar AA, Pandey P, Kamel I, Pawlik TM. Monitoring outcomes in intrahepatic cholangiocarcinoma patients following hepatic resection. Hepat Oncol. 2016;3(4):223–39. · DOI
- Takayasu K, Arii S, Ikai I, et al. Overall survival after transarterial lipiodol infusion chemotherapy with or without embolization for unresectable hepatocellular carcinoma: propensity score analysis. AJR Am J Roentgenol. 2010;194(3):830–7. · DOI
- Kim DY, Ryu HJ, Choi JY, et al. Radiological response predicts survival following transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma. Aliment Pharmacol Ther. 2012;35(11):1343–50. · DOI
- Arora A, Kumar A. Treatment Response Evaluation and Follow-up in Hepatocellular Carcinoma. J Clin Exp Hepatol. 2014;4(Suppl 3):S126-129. · doi:10.1016/j.jceh.2014.05.005
- Liu W, Zheng Y, Zou R, et al. Impact of follow-up interval on patients with hepatocellular carcinoma after curative ablation. BMC Cancer. 2018;18(1):1186. · doi:10.1186/s12885-018-5069-z
- Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis. 2010;30(1):52–60. · DOI · Paper page
- Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 11). Eur J Cancer. 2009;45(2):228–47. · DOI · Paper page
- Lucidarme O, Wagner M, Gillard P, et al. RECIST and CHOI criteria in the evaluation of tumor response in patients with metastatic colorectal cancer treated with regorafenib, a prospective multicenter study. Cancer Imaging. 2019;19(1):85. · doi:10.1186/s40644-019-0271-z
- Kadalayil L, Benini R, Pallan L, et al. A simple prognostic scoring system for patients receiving transarterial embolisation for hepatocellular cancer. Ann Oncol. 2013;24(10):2565–70. · DOI · Paper page
- Hucke F, Pinter M, Graziadei I, et al. How to STATE suitability and START transarterial chemoembolization in patients with intermediate stage hepatocellular carcinoma. J Hepatol. 2014;61(6):1287–96. · DOI · Paper page
- Wang Q, Xia D, Bai W, et al. Development of a prognostic score for recommended TACE candidates with hepatocellular carcinoma: A multicentre observational study. J Hepatol. 2019;70(5):893–903. · DOI · Paper page
- Terzi E, Terenzi L, Venerandi L, et al. The ART score is not effective to select patients for transarterial chemoembolization retreatment in an Italian series. Dig Dis. 2014;32(6):711–6. · DOI
- Kudo M, Arizumi T, Ueshima K. Assessment for retreatment (ART) score for repeated transarterial chemoembolization in patients with hepatocellular carcinoma. Hepatology. 2014;59(6):2424–5. · DOI
- Forner A, Gilabert M, Bruix J, Raoul JL. Treatment of intermediate-stage hepatocellular carcinoma. Nature reviews Clin Oncol. 2014;11(9):525–35. · DOI · Paper page
- Olweny CL, Toya T, Katongole-Mbidde E, Mugerwa J, Kyalwazi SK, Cohen H. Treatment of hepatocellular carcinoma with adriamycin. Preliminary commun Cancer. 1975;36(4):1250–7.
- Kawai S, Tani M, Okamura J, et al. Prospective and randomized trial of lipiodol-transcatheter arterial chemoembolization for treatment of hepatocellular carcinoma: a comparison of epirubicin and doxorubicin (second cooperative study). The Cooperative Study Group for Liver Cancer Treatment of Japan. Semin Oncol. 1997;24:S6-38-s36-45.
- Watanabe S, Nishioka M, Ohta Y, Ogawa N, Ito S, Yamamoto Y. Prospective and randomized controlled study of chemoembolization therapy in patients with advanced hepatocellular carcinoma Cooperative Study Group for Liver Cancer Treatment in Shikoku area. Cancer Chemother Pharmacol. 1994;33:S93-96. · doi:10.1007/bf00686676
- Shi M, Lu LG, Fang WQ, et al. Roles played by chemolipiodolization and embolization in chemoembolization for hepatocellular carcinoma: single-blind, randomized trial. J Natl Cancer Inst. 2013;105(1):59–68. · DOI
- Boulin M, Hillon P, Cercueil JP, et al. Idarubicin-loaded beads for chemoembolisation of hepatocellular carcinoma: results of the IDASPHERE phase I trial. Aliment Pharmacol Ther. 2014;39(11):1301–13. · doi:10.1111/apt.12746
- Favelier S, Boulin M, Hamza S, et al. Lipiodol trans-arterial chemoembolization of hepatocellular carcinoma with idarubicin: first experience. Cardiovasc Intervent Radiol. 2013;36(4):1039–46. · doi:10.1007/s00270-012-0532-8
- Guiu B, Chevallier P, Assenat E, et al. Idarubicin-loaded Beads for Chemoembolization of Hepatocellular Carcinoma: The IDASPHERE II Single-Arm Phase II Trial. Radiology. 2019;291(3):801–8. · doi:10.1148/radiol.2019182399
- Guiu B, Jouve JL, Schmitt A, et al. Intra-arterial idarubicin_lipiodol without embolisation in hepatocellular carcinoma: The LIDA-B phase I trial. J Hepatol. 2018;68(6):1163–71. · doi:10.1016/j.jhep.2018.01.022
- Sergio A, Cristofori C, Cardin R, et al. Transcatheter arterial chemoembolization (TACE) in hepatocellular carcinoma (HCC): the role of angiogenesis and invasiveness. Am J Gastroenterol. 2008;103(4):914–21. · DOI · Paper page
- Kudo M, Ueshima K, Ikeda M, et al. Randomised, multicentre prospective trial of transarterial chemoembolisation (TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial. Gut. 2020;69(8):1492. · DOI · Paper page
- Sakamoto I, Aso N, Nagaoki K, et al. Complications associated with transcatheter arterial embolization for hepatic tumors. Radiographics. 1998;18(3):605–19. · doi:10.1148/radiographics.18.3.9599386
Cited by
Minici, R., Serra, R., Maglia, C., Guzzardi, G., Spinetta, M., Fontana, F., Venturini, M., & Laganà, D. (2023) · Journal of Personalized Medicine · doi:10.3390/jpm13050812 · Cited by 20
Metadata
- Authors
- Lucatelli, P., Burrel, M., Guiu, B., de Rubeis, G., van Delden, O., & Helmberger, T.
- ORCID
- Lucatelli, Pierleone
- Venue
- CardioVascular and Interventional Radiology
- Published
- 2021-10-25
- Volume
- 44
- Issue
- 12
- Pages
- 1851-1867
- ISSN
- 0174-1551
- 1432-086X
- Cited by
- 101
- References
- 3
- Language
- en
- Licence
- www.springernature.com/gp/researchers/text-and-data-mining (tdm)
- www.springernature.com/gp/researchers/text-and-data-mining (vor)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: CIRSE Standards of Practice on Hepatic Transarterial Chemoembolisation. https://app.cochat.ai/papers/10.1007/s00270-021-02968-1
- The paper
- Lucatelli, P., Burrel, M., Guiu, B., de Rubeis, G., van Delden, O., & Helmberger, T. (2021). CIRSE Standards of Practice on Hepatic Transarterial Chemoembolisation. CardioVascular and Interventional Radiology. https://doi.org/10.1007/s00270-021-02968-1
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.